Stefano Cattaneo

Stefano Cattaneo

Auto-generated profile, based on publicly available information

Stefano Cattaneo

Vita-Salute San Raffaele University, 20132, Milan, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2017 in Molecular Therapy
Verified
Journal Article
Open access
GMGiuseppe Morabito
Giuseppe Morabito
SGSerena G. Giannelli
Serena G. Giannelli
GOGabriele Ordazzo
Gabriele Ordazzo
SBSimone Bido
Simone Bido
VCValerio Castoldi
Valerio Castoldi
VBVania Broccoli
Vania Broccoli
The lack of technology for direct global-scale targeting of the adult mouse nervous system has hindered research on brain processing and dysfunctions. Currently, gene transfer is normally achieved by intraparenchymal viral injections, but these injections target a restricted brain area. Herein, we demonstrated that intravenous delivery of adeno-associated virus (AAV)-PHP.B viral particles permeated and diffused throughout the neural parenchyma, targeting both the central and the peripheral nervous system in a global pattern. We then established multiple procedures of viral transduction to control gene expression or inactivate gene function exclusively in the adult nervous system and assessed the underlying behavioral effects. Building on these results, we established an effective gene therapy strategy to counteract the widespread accumulation of α-synuclein deposits throughout the forebrain in a mouse model of synucleinopathy. Transduction of A53T-SCNA transgenic mice with AAV-PHP.B-GBA1 restored physiological levels of the enzyme, reduced α-synuclein pathology, and produced significant behavioral recovery. Finally, we provided evidence that AAV-PHP.B brain penetration does not lead to evident dysfunctions in blood-brain barrier integrity or permeability. Altogether, the AAV-PHP.B viral platform enables non-invasive, widespread, and long-lasting global neural expression of therapeutic genes, such as GBA1, providing an invaluable approach to treat neurodegenerative diseases with diffuse brain pathology such as synucleinopathies.

1 October 2019 in Neuron
Verified
Journal Article
Closed access
ASAlessandro Sessa
Alessandro Sessa
LFLuca Fagnocchi
Luca Fagnocchi
GMGiuseppina Mastrototaro
Giuseppina Mastrototaro
LMLuca Massimino
Luca Massimino
MZMattia Zaghi
Mattia Zaghi
VBVania Broccoli
Vania Broccoli

18 December 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ECElena Chiricozzi
Elena Chiricozzi
LMLaura Mauri
Laura Mauri
GLGiulia Lunghi
Giulia Lunghi
EBErika Di Biase
Erika Di Biase
MFMaria Fazzari
Maria Fazzari
Sandro SonninoSandro Sonnino
Sandro Sonnino
Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1+/− mice, a model of sporadic Parkinson’s disease. We found that the GM1 oligosaccharide, systemically administered, reaches the brain and completely rescues the physical symptoms, reduces the abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal neurotransmitter levels, overlapping the wild-type condition. Thus, this study supports the idea that the Parkinson’s phenotype expressed by the B4galnt1+/− mice is due to a reduced level of neuronal ganglioside content and lack of interactions between the oligosaccharide portion of GM1 with specific membrane proteins. It also points to the therapeutic potential of the GM1 oligosaccharide for treatment of sporadic Parkinson’s disease.

8 December 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
EBErica Butti
Erica Butti
SCStefano Cattaneo
Stefano Cattaneo
MBMarco Bacigaluppi
Marco Bacigaluppi
MCMarco Cambiaghi
Marco Cambiaghi
GSGiulia Maria Scotti
Giulia Maria Scotti
GMGianvito Martino
Gianvito Martino
The adult brain retains over life endogenous neural stem/precursor cells (eNPCs) within the subventricular zone (SVZ). Whether or not these cells exert physiological functions is still unclear. In the present work, we provide evidence that SVZ-eNPCs tune structural, electrophysiological, and behavioural aspects of striatal function via secretion of insulin-like growth factor binding protein-like 1 (IGFBPL1). In mice, selective ablation of SVZ-eNPCs or selective abrogation of IGFBPL1 determined an impairment of striatal medium spiny neuron morphology, a higher failure rate in GABAergic transmission mediated by fast-spiking interneurons, and striatum-related behavioural dysfunctions. We also found IGFBPL1 expression in the human SVZ, foetal and induced-pluripotent stem cell-derived NPCs. Finally, we found a significant correlation between SVZ damage, reduction of striatum volume, and impairment of information processing speed in neurological patients. Our results highlight the physiological role of adult SVZ-eNPCs in supporting cognitive functions by regulating striatal neuronal activity.

1 January 2019 in Epilepsy Currents
Verified
Journal Article
Open access
PDF file
SISelene Ingusci
Selene Ingusci
SCStefano Cattaneo
Stefano Cattaneo
GVGianluca Verlengia
Gianluca Verlengia
SZSilvia Zucchini
Silvia Zucchini
MSMichele Simonato
Michele Simonato
Gene therapy has recently advanced to the level of standard of care for several diseases. However, its application to neurological disorders is still in the experimental phase. In this review, we discuss recent advancements in the field that provide optimism on the possibility to have first-in-human studies for gene therapy of some forms of epilepsy in the not so distant future.

1 June 2021 in Molecular Therapy - Methods & Clinical Development
Verified
Journal Article
Open access
MSMarie Soukupová
Marie Soukupová
SZSilvia Zucchini
Silvia Zucchini
PTPascal Trempat
Pascal Trempat
SISelene Ingusci
Selene Ingusci
CPColine Perrier-Biollay
Coline Perrier-Biollay
MSMichele Simonato
Michele Simonato
A key factor for developing gene therapy strategies for neurological disorders is the availability of suitable vectors. Currently, the most advanced are adeno-associated vectors that, while being safe and ensuring long-lasting transgene expression, have a very limited cargo capacity. In contrast, herpes simplex virus-based amplicon vectors can host huge amounts of foreign DNA, but concerns exist about their safety and ability to express transgenes long-term. We aimed at modulating and prolonging amplicon-induced transgene expression kinetics in vivo using different promoters and preventing transgene silencing. To pursue the latter, we deleted bacterial DNA sequences derived from vector construction and shielded the transgene cassette using AT-rich and insulator-like sequences (SAm technology). We employed luciferase and GFP as reporter genes. To determine transgene expression kinetics, we injected vectors in the hippocampus of mice that were longitudinally scanned for bioluminescence for 6 months. To evaluate safety, we analyzed multiple markers of damage and performed patch clamp electrophysiology experiments. All vectors proved safe, and we managed to modulate the duration of transgene expression, up to obtaining a stable, long-lasting expression using the SAm technology. Therefore, these amplicon vectors represent a flexible, efficient, and safe tool for gene delivery in the brain.